How to buy Agenus shares | 05 March price $3.06

How to buy Agenus shares | $3.06

Own Agenus shares in just a few minutes. Share price changes are updated daily.

Posted

Fact checked

Agenus Inc (AGEN) is a leading biotechnology business based in the US. It opened the day at $3.26 after a previous close of $3.16. During the day the price has varied from a low of $2.94 to a high of $3.35. The latest price was $3.06 (25 minute delay). Agenus is listed on the NASDAQ and employs 328 staff. All prices are listed in US Dollars.

How to buy shares in Agenus

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AGEN in this case.
  5. Research Agenus shares. The platform should provide the latest information available.
  6. Buy your Agenus shares. It's that simple.
The whole process can take as little as 15 minutes.

Agenus share price

Use our graph to track the performance of AGEN stocks over time.

Agenus shares at a glance

Information last updated 2021-03-05.
Open$3.26
High$3.35
Low$2.94
Close$3.06
Previous close$3.16
Change $-0.1
Change % -3.1646%
Volume 1,736,418
Information last updated 2021-03-03.
52-week range$1.82 - $5.45
50-day moving average $4.1256
200-day moving average $3.9828
Wall St. target price$8
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.906
Promoted
eToro Free Stocks

Invest in Agenus shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Fees for buying 100x Agenus shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
Fineco logo £0 No minimum £5.10
£226.59 total
Capital at risk
eToro Free Stocks logo £0 $500 £1.11
£222.59 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £0.94
£222.43 total
Capital at risk
Stake logo £0 £50 £1.40
£222.88 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £14.45
£235.94 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £11.60
£233.08 total
Capital at risk
Halifax Share Dealing Account logo £0 £20 £15.56
£237.04 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Agenus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Agenus price performance over time

Historical closes compared with the last close of $3.06

1 week (2021-02-26) -23.50%
1 month (2021-02-05) -40.93%
3 months (2020-12-04) -8.11%
6 months (2020-09-04) -21.94%
1 year (2020-03-05) 25.41%
2 years (2019-03-05) 6.25%
3 years (2018-03-05) -48.91%
5 years (2016-03-04) -20.31%

Agenus financials

Revenue TTM $91.4 million
Gross profit TTM $-18,291,000
Return on assets TTM -34.78%
Return on equity TTM 0%
Profit margin -189.66%
Market capitalisation $660.8 million

TTM: trailing 12 months

How to short and sell Agenus shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "AGEN.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 23.8 million Agenus shares held short by investors – that's known as Agenus's "short interest". This figure is 4.6% down from 25.0 million last month.

There are a few different ways that this level of interest in shorting Agenus shares can be evaluated.

Agenus's "short interest ratio" (SIR)

Agenus's "short interest ratio" (SIR) is the quantity of Agenus shares currently shorted divided by the average quantity of Agenus shares traded daily (recently around 3.9 million). Agenus's SIR currently stands at 6.05. In other words for every 100,000 Agenus shares traded daily on the market, roughly 6050 shares are currently held short.

However Agenus's short interest can also be evaluated against the total number of Agenus shares, or, against the total number of tradable Agenus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agenus's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Agenus shares in existence, roughly 130 shares are currently held short) or 0.1395% of the tradable shares (for every 100,000 tradable Agenus shares, roughly 140 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Agenus.

Find out more about how you can short Agenus stock.

Agenus share dividends

We're not expecting Agenus to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have Agenus's shares ever split?

Agenus's shares were split on a 1:6 basis on 3 October 2011. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Agenus shares which in turn could have impacted Agenus's share price.

Agenus share price volatility

Over the last 12 months, Agenus's shares have ranged in value from as little as $1.82 up to $5.45. A popular way to gauge a stock's volatility is its "beta".

AGEN.US volatility(beta: 1.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.6686. This would suggest that Agenus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Agenus overview

Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Frequently asked questions

More guides on Finder

  • How to buy Vroom shares | $27.97

    Learn more about Vroom’s recent performance and where you can invest in Vroom shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Washington Prime shares | $1.87

    Learn more about Washington Prime Group’s recent performance and where you can invest in Washington Prime shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Vertu Capital shares | 1.75p

    Learn more about Vertu Capital’s recent performance and where you can invest in Vertu Capital shares. We also run through some helpful rules of thumb for any investor.

  • How to buy ReTo Eco-Solutions shares | $1.66

    Learn more about ReTo Eco-Solutions’ recent performance and where you can invest in ReTo Eco-Solutions shares. We also run through some helpful rules of thumb for any investor.

  • How to buy RCI Hospitality Holdings shares

    Ever wondered how to buy shares in RCI Hospitality Holdings? We explain how and compare a range of providers that can give you access to many brands, including RCI Hospitality Holdings.

  • How to buy Norfolk Southern shares

    Ever wondered how to buy shares in Norfolk Southern? We explain how and compare a range of providers that can give you access to many brands, including Norfolk Southern.

  • How to buy ResMed shares

    Ever wondered how to buy shares in ResMed? We explain how and compare a range of providers that can give you access to many brands, including ResMed.

  • How to buy Motorola Solutions shares

    Ever wondered how to buy shares in Motorola Solutions? We explain how and compare a range of providers that can give you access to many brands, including Motorola Solutions.

  • How to buy Kinder Morgan shares

    Ever wondered how to buy shares in Kinder Morgan? We explain how and compare a range of providers that can give you access to many brands, including Kinder Morgan.

  • How to buy Enterprise Products Partners shares

    Ever wondered how to buy shares in Enterprise Products Partners? We explain how and compare a range of providers that can give you access to many brands, including Enterprise Products Partners.

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site